Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study

Abstract Introduction The B cell survival factor B lymphocyte stimulator (BLyS) is elevated in patients with systemic lupus erythematosus (SLE) and associated with disease activity. Belimumab, a monoclonal antibody specific for soluble BLyS, is approved for the treatment of adults with active, autoa...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jing Zhang, Weiguo Wan, Liyan Miao, Jian Wu, Jun Dong, Yinghua Shen, Cui Xiong, Chao Li, Yu Xue, Guoying Cao, Peiming Ma
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Adis, Springer Healthcare 2020-01-01
Saila:	Rheumatology and Therapy
Gaiak:	Belimumab Chinese ethnicity Pharmacodynamics Pharmacokinetics Systemic lupus erythematosus
Sarrera elektronikoa:	https://doi.org/10.1007/s40744-020-00193-9
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!